Neurosymbolic AI infrastructure for pharmaceutical/biotech companies, HTA bodies, CROs, policymakers and market-access consultancies to accelerate therapy access via reimbursement strategy, value demonstration, pricing and payer negotiation. Deterministic reasoning with confidence-calibration and human-adjudication routing, validated SLR/LSR screening and ~98% data-extraction accuracy, plus HTA-committee simulation predicting reimbursement conditions (~97% precision) and recommendations (~93% accuracy).